Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status

A federal appeals court in New York told the U.S. Drug Enforcement Administration (DEA) to “promptly” reconsider its classification of cannabis as a Schedule 1 drug. While it’s unclear whether the DEA will act, such a move could have a wide-ranging impact on medical cannabis businesses and research. “I think you would see an increase in … Continue reading Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status